Zentalis Pharmaceuticals Files Q1 2025 10-Q
Ticker: ZNTL · Form: 10-Q · Filed: May 14, 2025 · CIK: 1725160
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
TL;DR
Zentalis Pharma dropped its Q1 2025 10-Q. Check financials.
AI Summary
Zentalis Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. Key financial data and operational highlights are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Zentalis Pharmaceuticals, crucial for understanding the company's trajectory in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Zentalis faces inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025 financial results)
- 12/31 2025 — Fiscal Year End (Indicates the company's fiscal year closes on December 31st)
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250514 (date) — Filing date
- 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (address) — Company's business and mailing address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 14, 2025.
What is Zentalis Pharmaceuticals' primary industry?
Zentalis Pharmaceuticals operates in the Pharmaceutical Preparations industry, SIC code 2834.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
What is the company's business address?
The company's business address is 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA 92121.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Zentalis Pharmaceuticals, Inc. (ZNTL).